Dollinger index

524 ENTREPRENEURSHIP CASE

2005

148.18

15.18

3.46

166.82

89.72

7.70

69.40

3.36

10.91

5.04

0.44

5.67

43.98

0.45

49.79

0.23

41.83

16.92

3.44

0.50

128.61

4.11

2.35

0.85

249.08

47.23

1.57

11.47

15.54

11.46

76.93

0.35

84.53

249.08

113.19

8.74

1.86

123.79

66.84

5.17

51.78

2.98

8.43

3.58

0.33

5.96

30.50

0.34

4.99

71.13

26.80

19.32

5.05

0.50

48.28

• 
  


• 
  

  0.39
  176.80

  
  

27.06

0.83

10.71

9.78

11.28

75.69

(0.97)

42.42

176.80

Statement of Revenue

For the year ending March (US$ million)

Revenue

Sale of products

Contract research services

Other income

Less:

Cost of goods sold

Cost of contract research services

Gross Profit

Less:

Research & Development expenses

Selling, general and admn. expenses

Depreciation

Interest

Income tax

Net Income

Balance Sheet

Assets

Current Assets

Cash and cash equivalent

Investments in marketable securities

Restricted time deposits

Trade receivables

Inventories

Others

Fixed Assets

Goodwill

Property, plant and machinery

Other investments

Loan to joint venture company

Other assets

Total Assets

Liabilities and stock equity

Liabilities

Accounts payable

Advance from customers

Short-term borrowings

Deferred taxes

Stockholders’ equity

Common stock

Authorized paid-up capital

Others

Retained earnings

Total Liabilities & Stock Equity

EXHIBIT 4 Biocon Financials, 2004–2005

SOURCE: Biocon Ltd. files.

2004